Periodontal Disease - Pipeline Assessment and Market Forecasts to 2018

Periodontal Disease - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist’s new report, “Periodontal Disease - Pipeline Assessment and Market Forecasts to 2018” is an essential source of information and analysis on the global periodontal disease market. The report identifies the key trends shaping and driving the global periodontal disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global periodontal disease sector. GlobalData estimated the global periodontal disease therapeutics market to be valued at $1,607m in 2010. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 6.4% and reach $2,638m in 2018. The treatment of periodontal disease is dominated by dental procedures and techniques such as scaling, root planing and surgery. Additionally, the locally applied antibiotics (LAAs) and systemic applied antibiotics are used as adjunctive/ maintenance therapies. The LAAs and systemic antibiotics commonly prescribed for periodontal disease include Periochip (chlorhexidine), Arestin (minocycline), Atridox (doxycycline) and Periostat (low dose doxycycline). During the historical period 2005-2010, a major barrier for the periodontal disease therapeutics market was the limited awareness among the individuals about the disease. Fear of pain during surgery and costs related with the treatment procedures resulted in low treatment rates. However, due to the efforts of National Insitute of Dental and Craniofacial Research and National Institute of Health (NIH), these inhibitions have reduced over the past couple of years, importantly; this trend is likely to continue in the future, thereby resulting in an increase in the treatment rates. Increasing prevalence of the periodontal disease is a major factor for growth of the market, moreover, it is estimated that the prevalence of periodontal disease would continue to increase through the forecast period 2018.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key driver and challenges of the global pneumonia market. Its scope includes -

• Annualized global periodontal disease market revenues data from 2005 to 2010, forecast for eight years to 2018.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include antibiotics (metronidazole + amoxicillin), KCB-1D (recombinant human fibroblast growth factor).
• Analysis of the current and future market competition in the global periodontal disease market. The key market players covered are Kaken Pharmaceutical, Scil Technology, and Fibrocell.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future periodontal disease market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global periodontal disease market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global periodontal disease market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global periodontal disease market landscape? - Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 PERIODONTAL DISEASE THERAPEUTICS: EXECUTIVE SUMMARY

2.1 The Periodontal Disease Market is Forecast to Show Growth until 2018
2.2 Need for New Therapies with Better Efficacy
2.3 Weak Pipeline Consists of Only 11 Molecules

3 PERIODONTAL DISEASE THERAPEUTICS: INTRODUCTION

3.1 Disease Overview
3.2 Etiology and Pathogenesis
3.3 Signs and Symptoms
3.4 Epidemiology
3.5 Socio-econiomic status and quality of life:
3.6 Diagnosis
3.7 Treatment and Management Pattern:
3.8 Referral Pathway
3.9 GlobalData Pipeline Report Guidance

4 PERIODONTAL DISEASE THERAPEUTICS: MARKET CHARACTERIZATION

4.1 Periodontal Disease Therapeutics Market Size (2005–2010) – Global
4.2 Periodontal Disease Therapeutics Market Forecast (2010–2018) – Global
4.3 Periodontal Disease Therapeutics Market Size (2005–2010) – The US
4.4 Periodontal Disease Therapeutics Market Forecast (2010–2018) – The US
4.5 Periodontal Disease Therapeutics Market Size (2005–2010) – The UK
4.6 Periodontal Disease Therapeutics Market Forecast (2010–2018) – The UK
4.7 Periodontal Disease Therapeutics Market Size (2005–2010) – France
4.8 Periodontal Disease Therapeutics Market Forecast (2010–2018) – France
4.9 Periodontal Disease Therapeutics Market Size (2005–2010) – Germany
4.10 Periodontal Disease Therapeutics Market Forecast (2010–2018) – Germany
4.11 Periodontal Disease Therapeutics Market Size (2005–2010) – Italy
4.12 Periodontal Disease Therapeutics Market Forecast (2010–2018) – Italy
4.13 Periodontal Disease Therapeutics Market Size (2005–2010) – Spain
4.14 Periodontal Disease Therapeutics Market Forecast (2010–2018) – Spain
4.15 Periodontal Disease Therapeutics Market Size (2005–2010) – Japan
4.16 Periodontal Disease Therapeutics Market Size (2010–2018) – Japan
4.17 Drivers and Barriers for the Periodontal Disease Therapeutics Market
  4.17.1 Drivers for Periodontal Disease Market
Ø Increase in Prevalence
  4.17.2 Barriers for Periodontal Disease Market
4.18 Opportunity and Unmet Need Analysis
4.19 Key Takeaway

5 PERIODONTAL DISEASE THERAPEUTICS: COMPETITIVE ASSESSMENT

5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles for the Major Marketed Products in the Periodontal Disease Therapeutics Market
  5.3.1 Periostat (doxycycline hyclate)
  5.3.2 Periochip (chlorhexidine gluconate)
  5.3.3 Arestin (minocycline hydrochloride microspheres)
  5.3.4 Atridox (doxycycline hyclate 10%)
5.4 Key Takeaway

6 PERIODONTAL DISEASE THERAPEUTICS MARKET: PIPELINE ASSESSMENT

6.1 Overview
6.2 Strategic Pipeline Assessment
6.3 Periodontal Disease Therapeutics Pipeline – Pipeline by Phases of Development
  6.3.1 Periodontal Disease Therapeutics – Regulatory Filed Products
  6.3.2 Periodontal Disease Therapeutics – Phase III Pipeline
  6.3.3 Periodontal Disease Therapeutics – Phase II Pipeline
  6.3.4 Periodontal Disease Therapeutics – Discovery and Pre-Clinical Pipeline
  6.3.5 Technology Trends Analytic Framework
6.4 Periodontal Disease Therapeutics Market – Pipeline by Mechanism of Action
6.5 Periodontal Disease Therapeutics – Promising Drugs under Clinical Development
6.6 Molecule Profile for Promising Drugs under Clinical Development
  6.6.1 KCB-1D (trafermin, bFGF: Basic fibroblast growth factor)
6.7 Key Takeaway

7 PERIODONTAL DISEASE THERAPEUTICS: CLINICAL TRIALS MAPPING

7.1 Clinical Trials by Region/Country (US, EU5 and Japan)
7.2 Clinical Trials by Phase
7.3 Clinical Trials by Trial Status
7.4 Clinical Trials by Sponsors
7.5 Top Companies Participating in Periodontal Disease Therapeutics Clinical Trials

8 PERIODONTAL DISEASE THERAPEUTICS: STRATEGIC ASSESSMENT

8.1 Key Events Impacting the Future Market
8.2 Periodontal Disease Therapeutics: Implications for Future Market Competition

9 PERIODONTAL DISEASE THERAPEUTICS: FUTURE PLAYERS

9.1 Introduction
9.2 Company Profiles
  9.2.1 Kaken Pharmaceutical
  9.2.2 Scil Technology
  9.2.3 Fibrocell
  9.2.4 Other Companies in the Periodontal Disease Therapeutics Market

10 PERIODONTAL DISEASE THERAPEUTICS: LICENSING AND PARTNERSHIP DEALS

11 PERIODONTAL DISEASE THERAPEUTICS: APPENDIX

11.1 Market Definitions
11.2 Abbreviations
11.3 Research Methodology
  11.3.1 Coverage
  11.3.2 Secondary Research
  11.3.3 Forecasting
  11.3.4 Primary Research
  11.3.5 Expert Panel Validation
11.4 Contact Us
11.5 Disclaimer
11.6 Bibliography

LIST OF TABLES

Table 1: Periodontal Disease Therapeutics Market, Global, Revenue ($bn), 2005–2010
Table 2: Periodontal Disease Therapeutics Market, Global, Forecast ($bn), 2010–2018
Table 3: Periodontal Disease Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 4: Periodontal Disease Therapeutics Market, The US, Forecast ($m), 2010–2018
Table 5: Periodontal Disease Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 6: Periodontal Disease Therapeutics Market, The UK, Forecast ($m), 2010–2018
Table 7: Periodontal Disease Therapeutics Market, France, Revenue ($m), 2005–2010
Table 8: Periodontal Disease Therapeutics Market, France, Forecast ($m), 2010–2018
Table 9: Periodontal Disease Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 10: Periodontal Disease Therapeutics Market, Germany, Forecast ($m), 2010–2018
Table 11: Periodontal Disease Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 12: Periodontal Disease Therapeutics Market, Italy, Forecast ($m), 2010–2018
Table 13: Periodontal Disease Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 14: Periodontal Disease Therapeutics Market, Spain, Forecast ($m), 2010–2018
Table 15: Periodontal Disease Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 16: Periodontal Disease Therapeutics Market, Japan, Forecast ($m), 2010–2018
Table 17: Periodontal Disease Therapeutics Product Profiles, Clinical Study – Periostat
Table 18: Periodontal Disease Therapeutics Product Profiles, Clinical Study – Periochip
Table 19: Periodontal Disease Therapeutics Product Profiles, Clinical Study – Arestin
Table 20: Periodontal Disease Therapeutics, Regulatory Filed Products, 2011
Table 21: Periodontal Disease Therapeutics, Phase III Pipeline, 2011
Table 22: Periodontal Disease Therapeutics, Phase II Pipeline, 2011
Table 23: Periodontal Disease Therapeutics, Discovery and Pre-Clinical Pipeline, 2011
Table 24: Periodontal Disease Therapeutics – Most Promising Drugs Under Clinical Development, 2011
Table 25: Periodontal Disease Therapeutics, Clinical Trials by Country, 2011
Table 26: Periodontal Disease Therapeutics - Clinical Trials by Phase, 2011
Table 27: Periodontal Disease Therapeutics, Clinical Trials by Status, 2011
Table 28: Periodontal Disease Therapeutics, Prominent Sponsors, 2011
Table 29: Periodontal Disease Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 30: Kaken Pharmaceutical Pipeline for Periodontal Disease, 2011
Table 31: Scil Technology, Pipeline for Periodontal Disease, 2011
Table 32: Fibrocell Pipeline for Periodontal Disease, 2011
Table 33: Periodontal Disease Therapeutics Market, Future Players
Table 34: Periodontal Disease Therapeutics, Global, Deals, 2009-2011

LIST OF FIGURES

Figure 1: Pneumonia Therapeutics Market, Global, Revenue and Forecast ($m), 2005-2018
Figure 2: Opportunity and Unmet Need – HCAP Segment in Pneumonia Therapeutics
Figure 3: Revised Classification of Pneumonia
Figure 4: Etiology of CAP
Figure 5: Severity Index
Figure 6: Management of CAP
Figure 7: Diagnosis and Management of HCAP
Figure 8: Pneumonia Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 9: Pneumonia Therapeutics Market, Global, Forecast ($m), 2010–2018
Figure 10: Pneumonia Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 11: Pneumonia Therapeutics Market, The US, Forecast ($m), 2010–2018
Figure 12: Pneumonia Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 13: Pneumonia Therapeutics Market, The UK, Forecast ($m), 2010–2018
Figure 14: Pneumonia Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 15: Pneumonia Therapeutics Market, France, Forecast ($m), 2010–2018
Figure 16: Pneumonia Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 17: Pneumonia Therapeutics Market, Germany, Forecast ($m), 2010–2018
Figure 18: Pneumonia Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 19: Pneumonia Therapeutics Market, Italy, Forecast ($m), 2010–2018
Figure 20: Pneumonia Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 21: Pneumonia Therapeutics Market, Spain, Forecast ($m), 2010–2018
Figure 22: Pneumonia Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 23: Pneumonia Therapeutics Market, Japan, Forecast ($m), 2010–2018
Figure 24: Pneumonia Therapeutics Market, Drivers and Restraints, 2011
Figure 25: Opportunity and Unmet Need – CAP Segment in Pneumonia Therapeutics
Figure 26: Opportunity and Unmet Need – HCAP Segment in Pneumonia Therapeutics
Figure 27: Pneumonia Therapeutics Market – CAP Treatment ,Strategic Competitor Assessment, 2011
Figure 28: Pneumonia Therapeutics Market –HCAP Treatment ,Strategic Competitor Assessment, 2011
Figure 29: Pneumonia Therapeutics – Pipeline by Phase of Clinical Development, 2011
Figure 30: Pneumonia Therapeutics, Clinical Pipeline by Mechanism Of Action, 2011
Figure 31: Pneumonia Therapeutics, Technology Trends Analytics Framework, 2011
Figure 32: Pneumonia Therapeutics, Technology Trends Analytics Framework, Description, 2011
Figure 33: Pneumonia Therapeutics – Clinical Trials by Country, 2011
Figure 34: Pneumonia Therapeutics – Clinical Trials by Phase, 2011
Figure 35: Pneumonia Therapeutics – Clinical Trials by Status, 2011
Figure 36: Pneumonia Therapeutics – Overall Sponsors, 2011
Figure 37: Pneumonia Therapeutics - Prominent Sponsors, 2011
Figure 38: Pneumonia Therapeutics – Top Companies Participating in Clinical Trials, 2011
Figure 39: Implications for Future Market Competition in Pneumonia Therapeutics Market, 2011
Figure 40: Pneumonia Therapeutics Market – Clinical Pipeline by Company , 2011
Figure 41: GlobalData Market Forecasting Model

COMPANIES MENTIONED

Kaken Pharmaceutical
Scil Technology
Fibrocell Skip to top